Vera Therapeutics (NASDAQ:VERA) CFO Sells $207,759.02 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sean Grant sold 4,949 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the sale, the chief financial officer owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $40.79 on Friday. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -8.75 and a beta of 1.16. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $56.05. The stock’s 50 day moving average is $46.32 and its 200-day moving average is $35.49.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period last year, the business earned ($0.72) earnings per share. Equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Institutional Investors Weigh In On Vera Therapeutics

A number of large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in Vera Therapeutics in the 4th quarter valued at about $297,000. Invesco Ltd. lifted its holdings in shares of Vera Therapeutics by 193.3% during the 4th quarter. Invesco Ltd. now owns 89,851 shares of the company’s stock worth $4,550,000 after acquiring an additional 59,219 shares during the period. KVP Capital Advisors LP acquired a new stake in shares of Vera Therapeutics during the 4th quarter worth approximately $1,656,000. XTX Topco Ltd bought a new position in Vera Therapeutics in the fourth quarter valued at approximately $508,000. Finally, Virtus Investment Advisers LLC increased its stake in Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after acquiring an additional 290 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a report on Friday, November 28th. Bank of America raised their target price on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Evercore lifted their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $78.80.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.